IP Verse

Daiichi Sankyo competitive analysis

Latest oppositions filed by Daiichi Sankyo

Explore patent oppositions filed by Daiichi Sankyo against competitors, revealing strategic technology disputes and market positioning.

Last updated on: Aug 27, 2026
Patent NumberTitleApplicantOpposition Date
EP2544680
Use Of Erbb3 Inhibitors In The Treatment Of Triple Negative And Basal-Like Breast CancersMERRIMACK PHARMACEUTICALSOct 13, 2015
EP1889631
Cell Growth InhibitionTHE VICTOR CHANG CARDIAC RESEARCH INSTITUTEJun 1, 2015

Latest patents of Daiichi Sankyo opposed by its competitors

Explore Daiichi Sankyo's recently opposed patents, revealing key competitive challenges and strategic patent disputes in the industry. Track oppositions filed by competitors to understand technology battlegrounds and assess potential risks.

Last updated on: Aug 27, 2026
Patent NumberPublication DateTitleTotal Oppositions
EP3677589
Nov 26, 2025Improved Method For Producing Antibody-Drug Conjugate1
EP2140867
Aug 16, 2023Pharmaceutical Composition2
EP3196304
Oct 6, 2021Method For Improved High Secretory Production Of Proteins1
EP3121274
Dec 18, 2019Method For Predicting Responsiveness To Cancer Treatment Using P300-Inhibiting Compound1
EP2210940
Jul 18, 2018Method For High-Level Secretion And Production Of Protein1
EP1978034
May 16, 2018Anti-Periostin Antibody And Pharmaceutical Composition For Preventing Or Treating Periostin-Related Disease Containing The Same1
EP2097754
Jan 24, 2018Activated Her3 As A Marker For Predicting Therapeutic Efficacy1
EP2548556
Aug 10, 2016Method For Improving Dissolvability Of Anticoagulant1
EP2374456
Aug 3, 2016Activated Blood Coagulation Factor X (Fxa) Inhibitor4
EP2206727
Apr 1, 2015Antibody Targeting Osteoclast-Related Protein Siglec-151

Latest PTAB cases involving Daiichi Sankyo

Discover the latest PTAB cases involving Daiichi Sankyo, highlighting their recent legal challenges and patent disputes.

Last updated on: Aug 29, 2026
Proceeding NumberFiling DatePetitionerRespondentStatus

Get alerts for PTAB Cases involving Daiichi Sankyo

PGR2023-00037Jun 16, 2023ONCUSP THERAPEUTICSDAIICHI SANKYOTerminated-Settled
PGR2021-00042Jan 22, 2021DAIICHI SANKYODORONINATerminated-Adverse Judgment
PGR2021-00042Jan 22, 2021DAIICHI SANKYOSEAGENTerminated-Adverse Judgment
PGR2021-00030Dec 23, 2020DAIICHI SANKYOSEAGENFinal Written Decision
IPR2015-01881Oct 5, 2015LUPINDAIICHI SANKYOFinal Written Decision
IPR2015-01882Oct 5, 2015LUPINDAIICHI SANKYOFinal Written Decision
IPR2015-01492Jun 26, 2015PANACEA BIOTECDAIICHI SANKYOInstitution Denied
IPR2015-01496Jun 26, 2015PANACEA BIOTECDAIICHI SANKYOInstitution Denied
IPR2015-00865Mar 13, 2015ACCORD HEALTHCAREDAIICHI SANKYOFinal Written Decision
IPR2015-00864Mar 12, 2015ACCORD HEALTHCAREDAIICHI SANKYOFinal Written Decision

Peer Comparison New

IP litigation analysis comparing Daiichi Sankyo with top 3 competitors. Includes complete PTAB case data and opposition data from 2018 onwards.

Last updated on: Aug 27, 2026
CompanyOppositions FiledOppositions FacedPTAB Cases FiledPTAB Cases Faced
DAIICHI SANKYO11337
ACCORD HEALTHCARE44 - 4 -
LUPIN1115 -
PANACEA BIOTEC - - 2 -